Virus vaccine could be bad for red hot glove stocks


Danny Wong, chief executive officer at Malaysia-based Areca Capital Sdn., said in an interview that investors will be better off taking some profits in glove stocks over the next few quarters as news on vaccine development has been positive. "Stocks have already rallied a lot, ” Wong said.

KUALA LUMPUR: The recent progress in developing a vaccine for the coronavirus is posing a threat to the meteoric rise of Malaysian glove-maker stocks, one of the hottest sectors in Asia amid the pandemic.

Shares in the sector’s biggest companies such as Top Glove Corp., Hartalega Holdings Bhd. and Supermax Corp. each dropped more than 6% on Tuesday on signs that the Trump administration may fast-track vaccines and treatments for coronavirus.

The U.S. is expanding access to a treatment involving blood plasma from recovered patients and the Financial Times separately reported Trump’s government is considering whether to bypass regulatory standards to accelerate an experimental vaccine.

Get 30% off with our ads free Premium Plan!

Monthly Plan

RM13.90/month
RM9.73 only

Billed as RM9.73 for the 1st month then RM13.90 thereafters.

Annual Plan

RM12.33/month
RM8.63/month

Billed as RM103.60 for the 1st year then RM148 thereafters.

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Business News

GDA stands firm on RM11 offer for MAHB despite directors' rejection
Ringgit expected to trade within narrow range next week amid holiday calm
Book speaks volumes about Penang food
Can Lotte Chemical Titan weather the challenges?
US market - prudence is golden
Litmus test for China
Boons and banes of the DRG
Navigating tomorrow’s markets today
Will these acquisitions pay off?
Lexis Hotel Group redefines luxury

Others Also Read